ReviewCurrent atherosclerosis reports2012
Niacin: the evidence, clinical use, and future directions.
Review in Current atherosclerosis reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Pooled it
- Association between dietary niacin intake and kidney stones in American adults.Scientific reports · 2025Article
- NADSub-cellular biochemistry · 2024Review
- Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions.The journals of gerontology. Series A, Biological sciences and medical sciences · 2023Review
- Melanocytotoxic chemicals and their toxic mechanisms.Toxicological research · 2022Review
- Balancing NADCellular and molecular life sciences : CMLS · 2022Review
- Significantly Elevated Levels of Plasma Nicotinamide, Pyridoxal, and Pyridoxamine Phosphate Levels in Obese Emirati Population: A Cross-Sectional Study.Molecules (Basel, Switzerland) · 2020Article
- NADFrontiers in physiology · 2020Review
- Activated niacin receptor HCA2 inhibits chemoattractant-mediated macrophage migration via Gβγ/PKC/ERK1/2 pathway and heterologous receptor desensitization.Scientific reports · 2017Article
- Plaque imaging to refine indications for emerging lipid-lowering drugs.European heart journal. Cardiovascular pharmacotherapy · 2017Review
- Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review.Blood transfusion = Trasfusione del sangue · 2016Review
- Consensus statement on management of dyslipidemia in Indian subjects.Indian heart journal · 2014Review
- A modified method for studying behavioral paradox of antioxidants and their disproportionate competitive kinetic effect to scavenge the peroxyl radical formation.TheScientificWorldJournal · 2014Article
- Nicotinuric acid: a potential marker of metabolic syndrome through a metabolomics-based approach.Diabetes care · 2013Article
- Nicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of FDA-approved niacin (nicotinic acid or vitamin B3) formulations at therapeutic doses, alone or in combination with statins or other lipid therapies, is safe, improves multiple lipid parameters, and reduces atherosclerosis progression. Niacin is unique as the most potent available lipid therapy to increase high-density lipoprotein (HDL) cholesterol and it significantly reduces lipoprotein(a). Through its action on the GPR109A receptor, niacin may also exert beneficial pleiotropic effects independent of changes in lipid levels, such as improving endothelial function and attenuating vascular inflammation. Studies evaluating the impact of niacin in statin-naïve patients on cardiovascular outcomes, or alone and in combination with statins or other lipid therapies on atherosclerosis progression, have been universally favorable. However, the widespread use of niacin to treat residual lipid abnormalities such as low HDL cholesterol, when used in combination with statins among patients achieving very low (<75 mg/dL) low-density lipoprotein cholesterol levels, is currently not supported by clinical outcome trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.